Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

Ongoren S., Eskazan A. E., Suzan V., Savci S., Ozunal I. E., Berk S., ...Daha Fazla

Hematology (Amsterdam, Netherlands), cilt.23, sa.4, ss.212-220, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/10245332.2017.1385193
  • Dergi Adı: Hematology (Amsterdam, Netherlands)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.212-220
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib -> nilotinib or imatinib -> dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT.